Top

Current Hypertension Reports

Published in:

02-11-2022 | Intrauterine Growth Restriction | Preeclampsia (VD Garovic, Section Editor)

Cardiovascular Dysfunction in Intrauterine Growth Restriction

Authors: Narayanappa Amruta, Hemanth Kumar Kandikattu, Suttira Intapad

Published in: Current Hypertension Reports | Issue 12/2022

Abstract

Purpose of Review

We highlight important new findings on cardiovascular dysfunction in intrauterine growth restriction.

Recent Findings

Intrauterine growth restriction (IUGR) is a multifactorial condition which negatively impacts neonatal growth during pregnancy and is associated with health problems during the lifespan. It affects 5–15% of all pregnancies in the USA and Europe with varying percentages in developing countries. Epidemiological studies have reported that IUGR is associated with the pathogenesis of hypertension, activation of the renin-angiotensin system (RAS), disruption in placental-mTORC and TGFβ signaling cascades, and endothelial dysfunction in IUGR fetuses, children, adolescents, and adults resulting in the development of cardiovascular diseases (CVD). Experimental studies are needed to investigate therapeutic measures to treat increased blood pressure (BP) and long-term CVD problems in people affected by IUGR.

Summary

We outline the mechanisms mediating fetal programming of hypertension in developing CVD. We have reviewed findings from different experimental models focusing on recent studies that demonstrate CVD in IUGR.

Alberry M, Soothill P. Management of fetal growth restriction. Arch Dis Child Fetal Neonatal Ed. 2007;92(1):F62–7. https://doi.org/10.1136/adc.2005.082297.CrossRefPubMedPubMedCentral

Damodaram M, Story L, Kulinskaya E, Rutherford M, Kumar S. Early adverse perinatal complications in preterm growth-restricted fetuses. Aust N Z J Obstet Gynaecol. 2011;51(3):204–9. https://doi.org/10.1111/j.1479-828X.2011.01299.x.CrossRefPubMed

Gebb J, Dar P. Colour Doppler ultrasound of spiral artery blood flow in the prediction of pre-eclampsia and intrauterine growth restriction. Best Pract Res Clin Obstet Gynaecol. 2011;25(3):355–66. https://doi.org/10.1016/j.bpobgyn.2011.01.008.CrossRefPubMed

Sharma D, Shastri S, Sharma P. Intrauterine growth restriction: antenatal and postnatal aspects. Clin Med Insights Pediatr. 2016;10:67–83. https://doi.org/10.4137/CMPed.S40070.CrossRefPubMedPubMedCentral

Romo A, Carceller R, Tobajas J. Intrauterine growth retardation (IUGR): epidemiology and etiology. Pediatr Endocrinol Rev. 2009;6(Suppl 3):332–6.PubMed

Barker DJ, Bull AR, Osmond C, Simmonds SJ. Fetal and placental size and risk of hypertension in adult life. BMJ. 1990;301(6746):259–62.CrossRefPubMedPubMedCentral

•• Pagidipati NJ, Gaziano TA. Estimating deaths from cardiovascular disease: a review of global methodologies of mortality measurement. Circulation. 2013;127(6):749–56. https://doi.org/10.1161/CIRCULATIONAHA.112.128413. This very useful review describes of global methodologies of mortality measurement for estimating deaths from cardiovascular disease.

Say L, Chou D, Gemmill A, Tuncalp O, Moller AB, Daniels J, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014;2(6):e323–33. https://doi.org/10.1016/S2214-109X(14)70227-X.CrossRefPubMed

Zandi-Nejad K, Luyckx VA, Brenner BM. Adult hypertension and kidney disease - the role of fetal programming. Hypertension. 2006;47(3):502–8. https://doi.org/10.1161/01.HYP.0000198544.09909.1a.CrossRefPubMed

10.

Staessen JA, Wang J, Bianchi G, Birkenhager WH. Essential hypertension. Lancet. 2003;361(9369):1629–41. https://doi.org/10.1016/S0140-6736(03)13302-8.CrossRefPubMed

11.

Hennig M, Fiedler S, Jux C, Thierfelder L, Drenckhahn JD. Prenatal mechanistic target of rapamycin complex 1 (m TORC1) inhibition by rapamycin treatment of pregnant mice causes intrauterine growth restriction and alters postnatal cardiac growth, morphology, and function. J Am Heart Assoc. 2017;6(8). https://doi.org/10.1161/JAHA.117.005506.

12.

Crispi F, Miranda J, Gratacos E. Long-term cardiovascular consequences of fetal growth restriction: biology, clinical implications, and opportunities for prevention of adult disease. Am J Obstet Gynecol. 2018;218(2S):S869–79. https://doi.org/10.1016/j.ajog.2017.12.012.CrossRefPubMed

13.

Lisowska M, Pietrucha T, Sakowicz A. Preeclampsia and related cardiovascular risk: common genetic background. Curr Hypertens Rep. 2018;20(8):71. https://doi.org/10.1007/s11906-018-0869-8.CrossRefPubMedPubMedCentral

14.

Gaccioli F, Lager S. Placental nutrient transport and intrauterine growth restriction. Front Physiol. 2016;7:40. https://doi.org/10.3389/fphys.2016.00040.CrossRefPubMedPubMedCentral

15.

Burton GJ, Jauniaux E. Pathophysiology of placental-derived fetal growth restriction. Am J Obstet Gynecol. 2018;218(2S):S745–61. https://doi.org/10.1016/j.ajog.2017.11.577.CrossRefPubMed

16.

Jansson N, Rosario FJ, Gaccioli F, Lager S, Jones HN, Roos S, et al. Activation of placental mTOR signaling and amino acid transporters in obese women giving birth to large babies. J Clin Endocrinol Metab. 2013;98(1):105–13. https://doi.org/10.1210/jc.2012-2667.CrossRefPubMed

17.

Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet. 2005;37(1):19–24. https://doi.org/10.1038/ng1494.CrossRefPubMed

18.

Economides DL, Nicolaides KH. Blood glucose and oxygen tension levels in small-for-gestational-age fetuses. Am J Obstet Gynecol. 1989;160(2):385–9.CrossRefPubMed

19.

Dimasuay KG, Boeuf P, Powell TL, Jansson T. Placental responses to changes in the maternal environment determine fetal growth. Front Physiol. 2016;7:12. https://doi.org/10.3389/fphys.2016.00012.CrossRefPubMedPubMedCentral

20.

Sati L, Soygur B, Celik-Ozenci C. Expression of mammalian target of rapamycin and downstream targets in normal and gestational diabetic human term placenta. Reprod Sci. 2016;23(3):324–32. https://doi.org/10.1177/1933719115602765.CrossRefPubMed

21.

Desforges M, Lacey HA, Glazier JD, Greenwood SL, Mynett KJ, Speake PF, et al. SNAT4 isoform of system A amino acid transporter is expressed in human placenta. Am J Physiol Cell Physiol. 2006;290(1):C305–12. https://doi.org/10.1152/ajpcell.00258.2005.CrossRefPubMed

22.

Gupta MB, Jansson T. Novel roles of mTOR signaling in regulating fetal growth. Biol Reprod. 2018. https://doi.org/10.1093/biolre/ioy249.CrossRefPubMedPubMedCentral

23.

Arsham AM, Howell JJ, Simon MC. A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J Biol Chem. 2003;278(32):29655–60. https://doi.org/10.1074/jbc.M212770200.CrossRefPubMed

24.

Um SH, D’Alessio D, Thomas G. Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1. Cell Metab. 2006;3(6):393–402. https://doi.org/10.1016/j.cmet.2006.05.003.CrossRefPubMed

25.

Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124(3):471–84. https://doi.org/10.1016/j.cell.2006.01.016.CrossRefPubMed

26.

Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM, et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell. 2009;137(5):873–86. https://doi.org/10.1016/j.cell.2009.03.046.CrossRefPubMedPubMedCentral

27.

Roos S, Lagerlof O, Wennergren M, Powell TL, Jansson T. Regulation of amino acid transporters by glucose and growth factors in cultured primary human trophoblast cells is mediated by mTOR signaling. Am J Physiol Cell Physiol. 2009;297(3):C723–31. https://doi.org/10.1152/ajpcell.00191.2009.CrossRefPubMed

28.

Spradley FT, Ge Y, Haynes BP, Granger JP, Anderson CD. Adrenergic receptor blockade attenuates placental ischemia-induced hypertension. Physiol Rep. 2018;6(17):e13814. https://doi.org/10.14814/phy2.13814.CrossRefPubMedPubMedCentral

29.

Spradley FT, Palei AC, Granger JP. Increased risk for the development of preeclampsia in obese pregnancies: weighing in on the mechanisms. Am J Physiol Regul Integr Comp Physiol. 2015;309(11):R1326–43. https://doi.org/10.1152/ajpregu.00178.2015.CrossRefPubMedPubMedCentral

30.

Chen Q, Stone P, Ching LM, Chamley L. A role for interleukin-6 in spreading endothelial cell activation after phagocytosis of necrotic trophoblastic material: implications for the pathogenesis of pre-eclampsia. J Pathol. 2009;217(1):122–30. https://doi.org/10.1002/path.2425.CrossRefPubMed

31.

Harradine KA, Akhurst RJ. Mutations of TGFbeta signaling molecules in human disease. Ann Med. 2006;38(6):403–14. https://doi.org/10.1080/07853890600919911.CrossRefPubMed

32.

Stojanovska V, Scherjon SA, Plosch T. Preeclampsia as modulator of offspring health. Biol Reprod. 2016;94(3). ARTN 53 https://doi.org/10.1095/biolreprod.115.135780.

33.

Palei AC, Spradley FT, Warrington JP, George EM, Granger JP. Pathophysiology of hypertension in pre-eclampsia: a lesson in integrative physiology. Acta Physiol (Oxf). 2013;208(3):224–33. https://doi.org/10.1111/apha.12106.CrossRefPubMed

34.

ten Dijke P, Arthur HM. Extracellular control of TGFbeta signalling in vascular development and disease. Nat Rev Mol Cell Biol. 2007;8(11):857–69. https://doi.org/10.1038/nrm2262.CrossRefPubMed

35.

Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12(6):642–9. https://doi.org/10.1038/nm1429.CrossRefPubMed

36.

Chauvin S, Yinon Y, Xu J, Ermini L, Sallais J, Tagliaferro A, et al. Aberrant TGFbeta signalling contributes to dysregulation of sphingolipid metabolism in intrauterine growth restriction. J Clin Endocrinol Metab. 2015;100(7):E986–96. https://doi.org/10.1210/jc.2015-1288.CrossRefPubMed

37.

Londhe VA, Maisonet TM, Lopez B, Shin BC, Huynh J, Devaskar SU. Retinoic acid rescues alveolar hypoplasia in the calorie-restricted developing rat lung. Am J Respir Cell Mol Biol. 2013;48(2):179–87. https://doi.org/10.1165/rcmb.2012-0229OC.CrossRefPubMedPubMedCentral

38.

Sava RI, March KL, Pepine CJ. Hypertension in pregnancy: taking cues from pathophysiology for clinical practice. Clin Cardiol. 2018;41(2):220–7. https://doi.org/10.1002/clc.22892.CrossRefPubMedPubMedCentral

39.

Intapad S, Warrington JP, Spradley FT, Palei AC, Drummond HA, Ryan MJ, et al. Reduced uterine perfusion pressure induces hypertension in the pregnant mouse. Am J Physiol Regul Integr Comp Physiol. 2014;307(11):R1353–7. https://doi.org/10.1152/ajpregu.00268.2014.CrossRefPubMedPubMedCentral

40.

Swanson AM, David AL. Animal models of fetal growth restriction: considerations for translational medicine. Placenta. 2015;36(6):623–30. https://doi.org/10.1016/j.placenta.2015.03.003.CrossRefPubMed

41.

Herrera EA, Schneider D, Alegria R, Figueroa E, Villanueva C, Farias M, et al. Intrauterine growth restriction in guinea pig impairs umbilical and systemic vascular function. Placenta. 2015;36(4):485–6. https://doi.org/10.1016/j.placenta.2015.01.437.CrossRef

42.

Lawrence DJ, Escott ME, Myers L, Intapad S, Lindsey SH, Bayer CL. Spectral photoacoustic imaging to estimate in vivo placental oxygenation during preeclampsia. Sci Rep. 2019;9(1):558. https://doi.org/10.1038/s41598-018-37310-2.CrossRefPubMedPubMedCentral

43.

Herrera EA, Alegria R, Farias M, Diaz-Lopez F, Hernandez C, Uauy R, et al. Assessment of in vivo fetal growth and placental vascular function in a novel intrauterine growth restriction model of progressive uterine artery occlusion in guinea pigs. J Physiol. 2016;594(6):1553–61. https://doi.org/10.1113/JP271467.CrossRefPubMedPubMedCentral

44.

Salavati N, Smies M, Ganzevoort W, Charles AK, Erwich JJ, Plosch T, et al. The possible role of placental morphometry in the detection of fetal growth restriction. Front Physiol. 2018;9:1884. https://doi.org/10.3389/fphys.2018.01884.CrossRefPubMed

45.

Carter DR, Beaupre GS. Skeletal function and form: mechanobiology of skeletal development, aging, and regeneration. Cambridge University Press; 2007.

46.

Kim JS, Kim KK, Baek HJ, Park KS. Effect of confounding factors on blood pressure estimation using pulse arrival time. Physiol Meas. 2008;29(5):615–24. https://doi.org/10.1088/0967-3334/29/5/007.CrossRefPubMed

47.

Ranasinghe P, Cooray DN, Jayawardena R, Katulanda P. The influence of family history of hypertension on disease prevalence and associated metabolic risk factors among Sri Lankan adults. BMC Public Health. 2015;15:576. https://doi.org/10.1186/s12889-015-1927-7.CrossRefPubMedPubMedCentral

48.

Intapad S, Ojeda NB, Dasinger JH, Alexander BT. Sex differences in the developmental origins of cardiovascular disease. Physiology (Bethesda). 2014;29(2):122–32. https://doi.org/10.1152/physiol.00045.2013.CrossRefPubMed

49.

Wikstrom AK, Haglund B, Olovsson M, Lindeberg SN. The risk of maternal ischaemic heart disease after gestational hypertensive disease. Bjog-an Int J Obstetrics Gynaecol. 2005;112(11):1486–91. https://doi.org/10.1111/j.1471-0528.2005.00733.x.CrossRef

50.

•• Intapad S, Dasinger JH, Johnson JM, Brown AD, Ojeda NB, Alexander BT. Male and female intrauterine growth-restricted offspring differ in blood pressure, renal function, and glucose homeostasis responses to a postnatal diet high in fat and sugar. Hypertension. 2019;HYPERTENSIONAHA-118. This study implicate male IUGR are resistant to impaired glucose homeostasis, whereas female IUGR are susceptible to metabolic dysfunction regardless of postnatal diet. Hence, moderation of fat and sugar intake may be warranted in those born low birth weight to ensure minimal risk for chronic disease.

51.

• Intapad S, Alexander BT. Pregnancy complications and later development of hypertension. Curr Cardiovasc Risk Rep. 2013;7(3):183–9. https://doi.org/10.1007/s12170-013-0303-3. The authors provide one of the most comprehensive and all-inclusive reviews on increased blood pressure in the mother following a complicated pregnancy and provide insight into the development of preventative measures that may improve the long-term cardiovascular health of women and their offspring.CrossRefPubMedPubMedCentral

52.

Ojeda NB, Grigore D, Robertson EB, Alexander BT. Estrogen protects against increased blood pressure in postpubertal female growth restricted offspring. Hypertension. 2007;50(4):679–85. https://doi.org/10.1161/HYPERTENSIONAHA.107.091785.CrossRefPubMed

53.

Yang J, Shang J, Zhang S, Li H, Liu H. The role of the renin-angiotensin-aldosterone system in preeclampsia: genetic polymorphisms and microRNA. J Mol Endocrinol. 2013;50(2):R53-66. https://doi.org/10.1530/JME-12-0216.CrossRefPubMed

54.

Sparks MA, Crowley SD, Gurley SB, Mirotsou M, Coffman TM. Classical renin-angiotensin system in kidney physiology. Compr Physiol. 2014;4(3):1201–28. https://doi.org/10.1002/cphy.c130040.CrossRefPubMedPubMedCentral

55.

Anton L, Brosnihan KB. Systemic and uteroplacental renin–angiotensin system in normal and pre-eclamptic pregnancies. Ther Adv Cardiovasc Dis. 2008;2(5):349–62. https://doi.org/10.1177/1753944708094529.CrossRefPubMed

56.

Shah DA, Khalil RA. Bioactive factors in uteroplacental and systemic circulation link placental ischemia to generalized vascular dysfunction in hypertensive pregnancy and preeclampsia. Biochem Pharmacol. 2015;95(4):211–26. https://doi.org/10.1016/j.bcp.2015.04.012.CrossRefPubMedPubMedCentral

57.

Davis GK, Newsome AD, Ojeda NB, Alexander BT. Effects of intrauterine growth restriction and female sex on future blood pressure and cardiovascular disease. Curr Hypertens Rep. 2017;19(2):13. https://doi.org/10.1007/s11906-017-0712-7.CrossRefPubMedPubMedCentral

58.

Intapad S, Dasinger JH, Fahling JM, Backstrom MA, Alexander BT. Testosterone is protective against impaired glucose metabolism in male intrauterine growth-restricted offspring. PLoS ONE. 2017;12(11):e0187843. https://doi.org/10.1371/journal.pone.0187843.CrossRefPubMedPubMedCentral

59.

Alexander BT. Placental insufficiency leads to development of hypertension in growth-restricted offspring. Hypertension. 2003;41(3):457–62. https://doi.org/10.1161/01.HYP.0000053448.95913.3D.CrossRefPubMed

60.

Intapad S, Dasinger JH, Brown AD, Fahling JM, Esters J, Alexander BT. Glucose intolerance develops prior to increased adiposity and accelerated cessation of estrous cyclicity in female growth-restricted rats. Pediatr Res. 2016;79(6):962–70. https://doi.org/10.1038/pr.2016.14.CrossRefPubMedPubMedCentral

61.

Alexander BT. Fetal programming of hypertension. Am J Physiol Regul Integr Comp Physiol. 2006;290(1):R1–10. https://doi.org/10.1152/ajpregu.00417.2005.CrossRefPubMed

62.

Waterland RA, Michels KB. Epigenetic epidemiology of the developmental origins hypothesis. Annu Rev Nutr. 2007;27:363–88. https://doi.org/10.1146/annurev.nutr.27.061406.093705.CrossRefPubMed

63.

Ness RB, Markovic N, Bass D, Harger G, Roberts JM. Family history of hypertension, heart disease, and stroke among women who develop hypertension in pregnancy. Obstet Gynecol. 2003;102(6):1366–71.PubMed

64.

•• Loset M, Johnson MP, Melton PE, Ang W, Huang RC, Mori TA, et al. Preeclampsia and cardiovascular disease share genetic risk factors on chromosome 2q22. Pregnancy Hypertens Int J Womens Cardiovasc Health. 2014;4(2):178–85. https://doi.org/10.1016/j.preghy.2014.03.005. Study investigated four different single nucleotide polymorphism (SNPs) risk variants Curr Hypertens Rep (2018) 20: 71 Page 7 of 8 71 on the following genes: lactase, low-density lipoprotein receptor-related protein 1B, rho family GTPase 3 and grancalcin. All of the tested SNPs were found to be associated with preeclampsia and known cardiovascular risk factors, suggesting that mentioned diseases have the same genetic background.CrossRef

65.

Romundstad PR, Magnussen EB, Smith GD, Vatten LJ. Hypertension in pregnancy and later cardiovascular risk: common antecedents? Circulation. 2010;122(6):579–84. https://doi.org/10.1161/CIRCULATIONAHA.110.943407.CrossRefPubMed

66.

Johansson A, Curran JE, Johnson MP, Freed KA, Fenstad MH, Bjorge L, et al. Identification of ACOX2 as a shared genetic risk factor for preeclampsia and cardiovascular disease. Eur J Hum Genet. 2011;19(7):796–800. https://doi.org/10.1038/ejhg.2011.19.CrossRefPubMedPubMedCentral

67.

Sima AV, Botez GM, Stancu CS, Manea A, Raicu M, Simionescu M. Effect of irreversibly glycated LDL in human vascular smooth muscle cells: lipid loading, oxidative and inflammatory stress. J Cell Mol Med. 2010;14(12):2790–802. https://doi.org/10.1111/j.1582-4934.2009.00933.x.CrossRefPubMed

68.

Groten T, Schleussner E, Lehmann T, Reister F, Holzer B, Danso KA, et al. eNOSI4 and EPHX1 polymorphisms affect maternal susceptibility to preeclampsia: analysis of five polymorphisms predisposing to cardiovascular disease in 279 Caucasian and 241 African women. Arch Gynecol Obstet. 2014;289(3):581–93. https://doi.org/10.1007/s00404-013-2991-9.CrossRefPubMed

69.

Laasanen MS, Toyras J, Hirvonen J, Saarakkala S, Korhonen RK, Nieminen MT, et al. Novel mechano-acoustic technique and instrument for diagnosis of cartilage degeneration. Physiol Meas. 2002;23(3):491–503.CrossRefPubMed

70.

Rahimi Z, Aghaei A, Rahimi Z, Vaisi-Raygani A. Endothelial nitric oxide synthase (eNOS) 4a/b and G894T polymorphisms and susceptibility to preeclampsia. J Reprod Infertil. 2013;14(4):184–9.PubMedPubMedCentral

71.

Duplain H, Burcelin R, Sartori C, Cook S, Egli M, Lepori M, et al. Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation. 2001;104(3):342–5.CrossRefPubMed

72.

Dias S, Pheiffer C, Abrahams Y, Rheeder P, Adam S. Molecular biomarkers for gestational diabetes mellitus. Int J Mol Sci. 2018;19(10). https://doi.org/10.3390/ijms19102926.

73.

International HapMap C, Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature. 2007;449(7164):851–61. https://doi.org/10.1038/nature06258.

74.

Aye IL, Lager S, Ramirez VI, Gaccioli F, Dudley DJ, Jansson T, et al. Increasing maternal body mass index is associated with systemic inflammation in the mother and the activation of distinct placental inflammatory pathways. Biol Reprod. 2014;90(6):129. https://doi.org/10.1095/biolreprod.113.116186.CrossRefPubMedPubMedCentral

75.

Johnson MP, Brennecke SP, East CE, Dyer TD, Roten LT, Proffitt JM, et al. Genetic dissection of the pre-eclampsia susceptibility locus on chromosome 2q22 reveals shared novel risk factors for cardiovascular disease. Mol Hum Reprod. 2013;19(7):423–37. https://doi.org/10.1093/molehr/gat011.CrossRefPubMedPubMedCentral

76.

Chen LW, Egan L, Li ZW, Greten FR, Kagnoff MF, Karin M. The two faces of IKK and NF-kappaB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nat Med. 2003;9(5):575–81. https://doi.org/10.1038/nm849.CrossRefPubMed

77.

Vaughan JE, Walsh SW. Activation of NF-kappaB in placentas of women with preeclampsia. Hypertens Pregnancy. 2012;31(2):243–51. https://doi.org/10.3109/10641955.2011.642436.CrossRefPubMedPubMedCentral

78.

Gonzalez-Tendero A, Torre I, Garcia-Canadilla P, Crispi F, Garcia-Garcia F, Dopazo J, et al. Intrauterine growth restriction is associated with cardiac ultrastructural and gene expression changes related to the energetic metabolism in a rabbit model. Am J Physiol Heart Circ Physiol. 2013;305(12):H1752–60. https://doi.org/10.1152/ajpheart.00514.2013.CrossRefPubMed

79.

Guitart-Mampel M, Gonzalez-Tendero A, Ninerola S, Moren C, Catalan-Garcia M, Gonzalez-Casacuberta I, et al. Cardiac and placental mitochondrial characterization in a rabbit model of intrauterine growth restriction. Biochim Biophys Acta Gen Subj. 2018;1862(5):1157–67. https://doi.org/10.1016/j.bbagen.2018.02.006.CrossRefPubMed

80.

• Hromadnikova I, Kotlabova K, Hympanova L, Krofta L. Cardiovascular and cerebrovascular disease associated microRNAs are dysregulated in placental tissues affected with gestational hypertension, preeclampsia and intrauterine growth restriction. PLoS ONE. 2015;10(9):e0138383. https://doi.org/10.1371/journal.pone.0138383. This study tested 32 microRNA gene expression profiles and found that two of them, miR-100-5p and miR-125b-5p, are especially engaged in preeclampsia development.CrossRefPubMedPubMedCentral

81.

Enquobahrie DA, Abetew DF, Sorensen TK, Willoughby D, Chidambaram K, Williams MA. Placental microRNA expression in pregnancies complicated by preeclampsia. Am J Obstet Gynecol. 2011;204(2):178 e12–21. https://doi.org/10.1016/j.ajog.2010.09.004.

82.

Morsing E, Liuba P, Fellman V, Marsal K, Brodszki J. Cardiovascular function in children born very preterm after intrauterine growth restriction with severely abnormal umbilical artery blood flow. Eur J Prev Cardiol. 2014;21(10):1257–66. https://doi.org/10.1177/2047487313486044.CrossRefPubMed

83.

Tang XL, Li Q, Rokosh G, Sanganalmath SK, Chen N, Ou Q, et al. Long-term outcome of administration of c-kit(POS) cardiac progenitor cells after acute myocardial infarction: transplanted cells do not become cardiomyocytes, but structural and functional improvement and proliferation of endogenous cells persist for at least one year. Circ Res. 2016;118(7):1091–105. https://doi.org/10.1161/CIRCRESAHA.115.307647.CrossRefPubMedPubMedCentral

84.

Lim K, Zimanyi MA, Black MJ. Effect of maternal protein restriction in rats on cardiac fibrosis and capillarization in adulthood. Pediatr Res. 2006;60(1):83–7. https://doi.org/10.1203/01.pdr.0000220361.08181.c3.CrossRefPubMed

85.

Perez-Cruz M, Crispi F, Fernandez MT, Parra JA, Valls A, Gomez Roig MD, et al. Cord blood biomarkers of cardiac dysfunction and damage in term growth-restricted fetuses classified by severity criteria. Fetal Diagn Ther. 2018;44(4):271–6. https://doi.org/10.1159/000484315.CrossRefPubMed

86.

Perez-Cruz M, Cruz-Lemini M, Fernandez MT, Parra JA, Bartrons J, Gomez-Roig MD, et al. Fetal cardiac function in late-onset intrauterine growth restriction vs small-for-gestational age, as defined by estimated fetal weight, cerebroplacental ratio and uterine artery Doppler. Ultrasound Obstet Gynecol. 2015;46(4):465–71. https://doi.org/10.1002/uog.14930.CrossRefPubMed

87.

Karamlou TB, Giraud GD, McKeogh DF, Jonker SS, Shen I, Ungerlieder RM, et al. Right ventricular remodeling in response to volume overload in fetal sheep. Am J Physiol Heart Circ Physiol. 2019. https://doi.org/10.1152/ajpheart.00439.2018.CrossRefPubMedPubMedCentral

88.

Wang KC, Zhang L, McMillen IC, Botting KJ, Duffield JA, Zhang S, et al. Fetal growth restriction and the programming of heart growth and cardiac insulin-like growth factor 2 expression in the lamb. J Physiol. 2011;589(Pt 19):4709–22. https://doi.org/10.1113/jphysiol.2011.211185.CrossRefPubMedPubMedCentral

89.

Camm EJ, Botting KJ, Sferruzzi-Perri AN. Near to one’s heart: the intimate relationship between the placenta and fetal heart. Front Physiol. 2018;9:629. https://doi.org/10.3389/fphys.2018.00629.CrossRefPubMedPubMedCentral

90.

Stacy V, De Matteo R, Brew N, Sozo F, Probyn ME, Harding R, et al. The influence of naturally occurring differences in birthweight on ventricular cardiomyocyte number in sheep. Anat Rec-Adv Integrative Anat Evol Biol. 2009;292(1):29–37. https://doi.org/10.1002/ar.20789.CrossRefPubMed

91.

Wang KC, Lim CH, McMillen IC, Duffield JA, Brooks DA, Morrison JL. Alteration of cardiac glucose metabolism in association to low birth weight: experimental evidence in lambs with left ventricular hypertrophy. Metabolism. 2013;62(11):1662–72. https://doi.org/10.1016/j.metabol.2013.06.013.CrossRefPubMed

92.

Briscoe TA, Rehn AE, Dieni S, Duncan JR, Wlodek ME, Owens JA, et al. Cardiovascular and renal disease in the adolescent guinea pig after chronic placental insufficiency. Am J Obstet Gynecol. 2004;191(3):847–55. https://doi.org/10.1016/j.ajog.2004.01.050.CrossRefPubMed

93.

Menendez-Castro C, Toka O, Fahlbusch F, Cordasic N, Wachtveitl R, Hilgers KF, et al. Impaired myocardial performance in a normotensive rat model of intrauterine growth restriction. Pediatr Res. 2014;75(6):697–706. https://doi.org/10.1038/pr.2014.27.CrossRefPubMed

94.

He Q, Liu X, Zhong Y, Xu SS, Zhang ZM, Tang LL, et al. Arginine bioavailability and endothelin-1 system in the regulation of vascular function of umbilical vein endothelial cells from intrauterine growth restricted newborns. Nutr Metab Cardiovasc Dis. 2018;28(12):1285–95. https://doi.org/10.1016/j.numecd.2018.09.002.CrossRefPubMed

95.

Monica FZ, Bian K, Murad F. The endothelium-dependent nitric oxide-cGMP pathway. Adv Pharmacol. 2016;77:1–27. https://doi.org/10.1016/bs.apha.2016.05.001.CrossRefPubMed

96.

Siragusa M, Fleming I. The eNOS signalosome and its link to endothelial dysfunction. Pflugers Archiv-Eur J Physiol. 2016;468(7):1125–37. https://doi.org/10.1007/s00424-016-1839-0.CrossRef

97.

Xu XF, Lv Y, Gu WZ, Tang LL, Wei JK, Zhang LY, et al. Epigenetics of hypoxic pulmonary arterial hypertension following intrauterine growth retardation rat: epigenetics in PAH following IUGR. Respir Res. 2013;14:20. https://doi.org/10.1186/1465-9921-14-20.CrossRefPubMedPubMedCentral

98.

Thorin E, Huang PL, Fishman MC, Bevan JA. Nitric oxide inhibits alpha(2)-adrenoceptor-mediated endothelium-dependent vasodilation. Circ Res. 1998;82(12):1323–9. https://doi.org/10.1161/01.Res.82.12.1323.CrossRefPubMed

99.

Xuan C, Tian QW, Li H, Zhang BB, He GW, Lun LM. Levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, and risk of coronary artery disease: a meta-analysis based on 4713 participants. Eur J Prev Cardiol. 2016;23(5):502–10. https://doi.org/10.1177/2047487315586094.CrossRefPubMed

100.

Tintu A, Rouwet E, Verlohren S, Brinkmann J, Ahmad S, Crispi F, et al. Hypoxia induces dilated cardiomyopathy in the chick embryo: mechanism, intervention, and long-term consequences. PLoS ONE. 2009;4(4):e5155. https://doi.org/10.1371/journal.pone.0005155.CrossRefPubMedPubMedCentral

101.

Crispi F, Figueras F, Cruz-Lemini M, Bartrons J, Bijnens B, Gratacos E. Cardiovascular programming in children born small for gestational age and relationship with prenatal signs of severity. Am J Obstetr Gynecol. 2012;207(2):121-e1. https://doi.org/10.1016/j.ajog.2012.05.011.

102.

Zanardo V, de Luca F, Trevisanuto D, Simbi A, Scambia G, Straface G. “Two-step” head-to-body delivery activates foetal gluconeogenesis. Acta Paediatr. 2013;102(7):e334–8. https://doi.org/10.1111/apa.12261.CrossRefPubMed

103.

Comas M, Crispi F, Cruz-Martinez R, Figueras F, Gratacos E. Tissue Doppler echocardiographic markers of cardiac dysfunction in small-for-gestational age fetuses. Am J Obstetr Gynecol. 2011;205(1):57-e1. https://doi.org/10.1016/j.ajog.2011.03.010.

104.

Cruz-Lemini M, Crispi F, Valenzuela-Alcaraz B, Figueras F, Gomez O, Sitges M, et al. A fetal cardiovascular score to predict infant hypertension and arterial remodeling in intrauterine growth restriction. Am J Obstet Gynecol. 2014;210(6):552 e1- e22. https://doi.org/10.1016/j.ajog.2013.12.031.

105.

Schlaudecker EP, Munoz FM, Bardaji A, Boghossian NS, Khalil A, Mousa H, et al. Small for gestational age: case definition & guidelines for data collection, analysis, and presentation of maternal immunisation safety data. Vaccine. 2017;35(48 Pt A):6518–28. https://doi.org/10.1016/j.vaccine.2017.01.040.

106.

Akazawa Y, Hachiya A, Yamazaki S, Kawasaki Y, Nakamura C, Takeuchi Y, et al. Cardiovascular remodeling and dysfunction across a range of growth restriction severity in small for gestational age infants - implications for fetal programming. Circ J. 2016;80(10):2212-+. https://doi.org/10.1253/circj.CJ-16-0352.

107.

Makikallio K, Vuolteenaho O, Jouppila P, Rasanen J. Ultrasonographic and biochemical markers of human fetal cardiac dysfunction in placental insufficiency. Circulation. 2002;105(17):2058–63. https://doi.org/10.1161/01.Cir.0000015505.24187.Fa.CrossRefPubMed

108.

Sehgal A, Paul E, Menahem S. Functional echocardiography in staging for ductal disease severity: role in predicting outcomes. Eur J Pediatr. 2013;172(2):179–84. https://doi.org/10.1007/s00431-012-1851-0.CrossRefPubMed

109.

Fouzas S, Karatza AA, Davlouros PA, Chrysis D, Alexopoulos D, Mantagos S, et al. Heterogeneity of ventricular repolarization in newborns with intrauterine growth restriction. Early Hum Dev. 2014;90(12):857–62. https://doi.org/10.1016/j.earlhumdev.2014.09.009.CrossRefPubMed

110.

Skilton MR, Pahkala K, Viikari JS, Ronnemaa T, Simell O, Jula A, et al. The association of dietary alpha-linolenic acid with blood pressure and subclinical atherosclerosis in people born small for gestational age: the Special Turku Coronary Risk Factor Intervention Project study. J Pediatr. 2015;166(5):1252–7 e2. https://doi.org/10.1016/j.jpeds.2015.01.020.

111.

Miles KL, McDonnell BJ, Maki-Petaja KM, Yasmin, Cockcroft JR, Wilkinson IB, et al. The impact of birth weight on blood pressure and arterial stiffness in later life: the Enigma Study. J Hypertens. 2011;29(12):2324–31. https://doi.org/10.1097/HJH.0b013e32834d0ca1.

112.

Hietalampi H, Pahkala K, Jokinen E, Ronnemaa T, Viikari JSA, Niinikoski H, et al. Left ventricular mass and geometry in adolescence early childhood determinants. Hypertension. 2012;60(5):1266–72. https://doi.org/10.1161/Hypertensionaha.112.194290.CrossRefPubMed

113.

Nam HK, Cho WK, Kim JH, Rhie YJ, Chung S, Lee KH, et al. HbA1c Cutoff for prediabetes and diabetes based on oral glucose tolerance test in obese children and adolescents. J Korean Med Sci. 2018;33(12):e93. https://doi.org/10.3346/jkms.2018.33.e93.CrossRefPubMedPubMedCentral

114.

West NA, Crume TL, Maligie MA, Dabelea D. Cardiovascular risk factors in children exposed to maternal diabetes in utero. Diabetologia. 2011;54(3):504–7. https://doi.org/10.1007/s00125-010-2008-1.CrossRefPubMed

115.

Dasinger JH, Alexander BT. Gender differences in developmental programming of cardiovascular diseases. Clin Sci (Lond). 2016;130(5):337–48. https://doi.org/10.1042/CS20150611.CrossRefPubMed

116.

Gaillard R, Steegers EA, Duijts L, Felix JF, Hofman A, Franco OH, et al. Childhood cardiometabolic outcomes of maternal obesity during pregnancy: the Generation R Study. Hypertension. 2014;63(4):683–91. https://doi.org/10.1161/HYPERTENSIONAHA.113.02671.CrossRefPubMed

117.

Intapad S. Reprogramming essential hypertension: the role of resveratrol. Hypertension. 2016;67(5):829–30. https://doi.org/10.1161/HYPERTENSIONAHA.116.06919.CrossRefPubMed

118.

Ojeda NB, Grigore D, Alexander BT. Intrauterine growth restriction: fetal programming of hypertension and kidney disease. Adv Chronic Kidney Dis. 2008;15(2):101–6. https://doi.org/10.1053/j.ackd.2008.01.001.CrossRefPubMedPubMedCentral

119.

Sholook MM, Gilbert JS, Sedeek MH, Huang M, Hester RL, Granger JP. Systemic hemodynamic and regional blood flow changes in response to chronic reductions in uterine perfusion pressure in pregnant rats. Am J Physiol-Heart and Circul Physiol. 2007;293(4):H2080–4. https://doi.org/10.1152/ajpheart.00667.2007.CrossRef

120.

Walsh SK, English FA, Johns EJ, Kenny LC. Plasma-mediated vascular dysfunction in the reduced uterine perfusion pressure model of preeclampsia: a microvascular characterization. Hypertension. 2009;54(2):345–51. https://doi.org/10.1161/HYPERTENSIONAHA.109.132191.CrossRefPubMed

121.

Granger JP, LaMarca BB, Cockrell K, Sedeek M, Balzi C, Chandler D, et al. Reduced uterine perfusion pressure (RUPP) model for studying cardiovascular-renal dysfunction in response to placental ischemia. Methods Mol Med. 2006;122:383–92.PubMed

122.

Gilbert JS, Gilbert SA, Arany M, Granger JP. Hypertension produced by placental ischemia in pregnant rats is associated with increased soluble endoglin expression. Hypertension. 2009;53(2):399–403. https://doi.org/10.1161/HYPERTENSIONAHA.108.123513.CrossRefPubMed

123.

Grosser N, Abate A, Oberle S, Vreman HJ, Dennery PA, Becker JC, et al. Heme oxygenase-1 induction may explain the antioxidant profile of aspirin. Biochem Biophys Res Commun. 2003;308(4):956–60.CrossRefPubMed

124.

Chassen S, Jansson T. Complex, coordinated and highly regulated changes in placental signaling and nutrient transport capacity in IUGR. Biochim Biophys Acta Mol Basis Dis. 2019.

125.

Fischer M, Baessler A, Schunkert H. Renin angiotensin system and gender differences in the cardiovascular system. Cardiovasc Res. 2002;53(3):672–7.CrossRefPubMed

126.

Ojeda NB, Royals TP, Black JT, Dasinger JH, Johnson JM, Alexander BT. Enhanced sensitivity to acute angiotensin II is testosterone dependent in adult male growth-restricted offspring. Am J Physiol Regul Integr Comp Physiol. 2010;298(5):R1421–7. https://doi.org/10.1152/ajpregu.00096.2010.CrossRefPubMedPubMedCentral

127.

Grigore D, Ojeda NB, Robertson EB, Dawson AS, Huffman CA, Bourassa EA, et al. Placental insufficiency results in temporal alterations in the renin angiotensin system in male hypertensive growth restricted offspring. Am J Physiol Regul Integr Comp Physiol. 2007;293(2):R804–11. https://doi.org/10.1152/ajpregu.00725.2006.CrossRefPubMed

128.

Huxley R, Neil A, Collins R. Unravelling the fetal origins hypothesis: is there really an inverse association between birthweight and subsequent blood pressure? Lancet. 2002;360(9334):659–65. https://doi.org/10.1016/S0140-6736(02)09834-3.CrossRefPubMed

129.

Alexander BT, Dasinger JH, Intapad S. Fetal programming and cardiovascular pathology. Compr Physiol. 2015;5(2):997–1025. https://doi.org/10.1002/cphy.c140036.CrossRefPubMedPubMedCentral

130.

Fortepiani LA, Zhang HM, Racusen L, Roberts LJ, Reckelhoff JF. Characterization of an animal model of postmenopausal hypertension in spontaneously hypertensive rats. Hypertension. 2003;41(3):640–5. https://doi.org/10.1161/01.Hyp.0000046924.94886.Ef.CrossRefPubMed

131.

Yanes LL, Romero DG, Iles JW, Iliescu R, Gomez-Sanchez C, Reckelhoff JF. Sexual dimorphism in the renin-angiotensin system in aging spontaneously hypertensive rats. Am J Physiol Regul Integr Comp Physiol. 2006;291(2):R383–90. https://doi.org/10.1152/ajpregu.00510.2005.CrossRefPubMed

132.

Brooks HL, Pollow DP, Hoyer PB. The VCD mouse model of menopause and perimenopause for the study of sex differences in cardiovascular disease and the metabolic syndrome. Physiology (Bethesda). 2016;31(4):250–7. https://doi.org/10.1152/physiol.00057.2014.CrossRefPubMed

133.

Liu Y, Wang Z, Li J, Ban Y, Mao G, Zhang M, et al. Inhibition of 5-hydroxytryptamine receptor 2B reduced vascular restenosis and mitigated the beta-arrestin2-mammalian target of rapamycin/p70S6K pathway. J Am Heart Assoc. 2018;7(3). https://doi.org/10.1161/JAHA.117.006810.

134.

Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 2006;22(2):159–68. https://doi.org/10.1016/j.molcel.2006.03.029.CrossRefPubMed

135.

Grandvuillemin I, Buffat C, Boubred F, Lamy E, Fromonot J, Charpiot P, et al. Arginase upregulation and eNOS uncoupling contribute to impaired endothelium-dependent vasodilation in a rat model of intrauterine growth restriction. Am J Physiol Regul Integr Comp Physiol. 2018;315(3):R509–20. https://doi.org/10.1152/ajpregu.00354.2017.CrossRefPubMed

136.

Yzydorczyk C, Armengaud JB, Peyter AC, Chehade H, Cachat F, Juvet C, et al. Endothelial dysfunction in individuals born after fetal growth restriction: cardiovascular and renal consequences and preventive approaches. J Dev Orig Health Dis. 2017;8(4):448–64. https://doi.org/10.1017/S2040174417000265.CrossRefPubMed

137.

Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111(5):649–58. https://doi.org/10.1172/JCI17189.CrossRefPubMedPubMedCentral

138.

McCarthy FP, Kingdom JC, Kenny LC, Walsh SK. Animal models of preeclampsia; uses and limitations. Placenta. 2011;32(6):413–9. https://doi.org/10.1016/j.placenta.2011.03.010.CrossRefPubMed

139.

Zhao Y, Vanhoutte PM, Leung SW. Vascular nitric oxide: beyond eNOS. J Pharmacol Sci. 2015;129(2):83–94. https://doi.org/10.1016/j.jphs.2015.09.002.CrossRefPubMed

140.

Payne JA, Alexander BT, Khalil RA. Reduced endothelial vascular relaxation in growth-restricted offspring of pregnant rats with reduced uterine perfusion. Hypertension. 2003;42(4):768–74. https://doi.org/10.1161/01.HYP.0000084990.88147.0C.CrossRefPubMed

141.

Sathishkumar K, Elkins R, Yallampalli U, Balakrishnan M, Yallampalli C. Fetal programming of adult hypertension in female rat offspring exposed to androgens in utero. Early Hum Dev. 2011;87(6):407–14. https://doi.org/10.1016/j.earlhumdev.2011.03.001.CrossRefPubMedPubMedCentral

142.

Ahmad A, Dempsey SK, Daneva Z, Li N, Poklis JL, Li PL, et al. Modulation of mean arterial pressure and diuresis by renomedullary infusion of a selective inhibitor of fatty acid amide hydrolase. Am J Physiol Renal Physiol. 2018;315(4):F967–76. https://doi.org/10.1152/ajprenal.00090.2018.CrossRefPubMedPubMedCentral

143.

Martin H, Hu J, Gennser G, Norman M. Impaired endothelial function and increased carotid stiffness in 9-year-old children with low birthweight. Circulation. 2000;102(22):2739–44. https://doi.org/10.1161/01.Cir.102.22.2739.CrossRefPubMed

144.

Goodfellow J, Bellamy MF, Gorman ST, Brownlee M, Ramsey MW, Lewis MJ, et al. Endothelial function is impaired in fit young adults of low birth weight. Cardiovasc Res. 1998;40(3):600–6. https://doi.org/10.1016/S0008-6363(98)00197-7.CrossRefPubMed

145.

Faas MM, Schuiling GA, Baller JF, Visscher CA, Bakker WW. A new animal model for human preeclampsia: ultra-low-dose endotoxin infusion in pregnant rats. Am J Obstet Gynecol. 1994;171(1):158–64.CrossRefPubMed

146.

Herrera EA, Krause B, Ebensperger G, Reyes RV, Casanello P, Parra-Cordero M, et al. The placental pursuit for an adequate oxidant balance between the mother and the fetus. Front Pharmacol. 2014;5:149. https://doi.org/10.3389/fphar.2014.00149.CrossRefPubMedPubMedCentral

147.

Thakor AS, Richter HG, Kane AD, Dunster C, Kelly FJ, Poston L, et al. Redox modulation of the fetal cardiovascular defence to hypoxaemia. J Physiol. 2010;588(Pt 21):4235–47. https://doi.org/10.1113/jphysiol.2010.196402.CrossRefPubMedPubMedCentral

148.

Xiao D, Huang X, Yang S, Zhang L. Estrogen normalizes perinatal nicotine-induced hypertensive responses in adult female rat offspring. Hypertension. 2013;61(6):1246–54. https://doi.org/10.1161/HYPERTENSIONAHA.113.01152.CrossRefPubMed

149.

Ojeda NB, Hennington BS, Williamson DT, Hill ML, Betson NE, Sartori-Valinotti JC, et al. Oxidative stress contributes to sex differences in blood pressure in adult growth-restricted offspring. Hypertension. 2012;60(1):114–22. https://doi.org/10.1161/HYPERTENSIONAHA.112.192955.CrossRefPubMed

150.

Tao H, Rui C, Zheng J, Tang J, Wu L, Shi A, et al. Angiotensin II-mediated vascular changes in aged offspring rats exposed to perinatal nicotine. Peptides. 2013;44:111–9. https://doi.org/10.1016/j.peptides.2013.02.019.CrossRefPubMed

151.

Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74(6):1141–8.CrossRefPubMed

152.

Chow AK, Cena J, Schulz R. Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature. Br J Pharmacol. 2007;152(2):189–205. https://doi.org/10.1038/sj.bjp.0707344.CrossRefPubMedPubMedCentral

153.

Zafari AM, Ushio-Fukai M, Akers M, Yin Q, Shah A, Harrison DG, et al. Role of NADH/NADPH oxidase-derived H2O2 in angiotensin II-induced vascular hypertrophy. Hypertension. 1998;32(3):488–95.CrossRefPubMed

154.

Rodriguez-Lopez M, Osorio L, Acosta-Rojas R, Figueras J, Cruz-Lemini M, Figueras F, et al. Influence of breastfeeding and postnatal nutrition on cardiovascular remodeling induced by fetal growth restriction. Pediatr Res. 2016;79(1–1):100–6. https://doi.org/10.1038/pr.2015.182.CrossRefPubMed

155.

• Terstappen F, Spradley FT, Bakrania BA, Clarke SM, Joles JA, Paauw ND, et al. Prenatal sildenafil therapy improves cardiovascular function in fetal growth restricted offspring of Dahl salt-sensitive rats. Hypertension. 2019;73(5):1120–7. https://doi.org/10.1161/HYPERTENSIONAHA.118.12454. This study showed translationally important, in utero treatment could be beneficial for cardiovascular programming in a sex-specific manner; however, caution is warranted since recent human trials have been halted because of potentially deleterious neonatal side effects when treating pregnancies complicated with severe FGR with sildenafil.

156.

Vaughan OR, Rossi CA, Ginsberg Y, White A, Hristova M, Sebire NJ, et al. Perinatal and long-term effects of maternal uterine artery adenoviral VEGF-A165 gene therapy in the growth-restricted guinea pig fetus. Am J Physiol Regul Integr Comp Physiol. 2018;315(2):R344–53. https://doi.org/10.1152/ajpregu.00210.2017.CrossRefPubMed

157.

Chimini JS, Possomato-Vieira JS, da Silva MLS, Dias-Junior CA. Placental nitric oxide formation and endothelium-dependent vasodilation underlie pravastatin effects against angiogenic imbalance, hypertension in pregnancy and intrauterine growth restriction. Basic Clin Pharmacol Toxicol. 2019;124(4):385–93. https://doi.org/10.1111/bcpt.13149.CrossRefPubMed

Title: Cardiovascular Dysfunction in Intrauterine Growth Restriction
Authors: Narayanappa Amruta
Hemanth Kumar Kandikattu
Suttira Intapad
Publication date: 02-11-2022
Publisher: Springer US
Keywords: Intrauterine Growth Restriction
Hypertension
Hypertension
Published in: Current Hypertension Reports / Issue 12/2022
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-022-01228-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 12/2022

Does the Naked Emperor Parable Apply to Current Perceptions of the Contribution of Renin Angiotensin System Inhibition in Hypertension?

Effects of Hypertension on Alzheimer’s Disease and Related Disorders

Hypoxia-Inducible Factor 1 and Preeclampsia: A New Perspective

Six Decades of History of Hypertension Research at the University of Toledo: Highlighting Pioneering Contributions in Biochemistry, Genetics, and Host-Microbiota Interactions

Strategies to Improve Medication Adherence and Blood Pressure Among Racial/Ethnic Minority Populations: A Scoping Review of the Literature from 2017 to 2021

Immune Cell Activation in Obesity and Cardiovascular Disease

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage